GU Cancers Symposium

“Obviously, patients benefit [from this regimen]. Not only can they enjoy longer life, but also their cancer is pretty much under control for a longer time, which is great,” says Karim Fizazi, MD, PhD

“I think results from this study introduce a new standard of care for patients with metastatic hormone-sensitive prostate cancer, where we clearly need to do better than what we're doing today, since the sequence of therapy seems to be less effective than hitting them hard upfront,” says Fred Saad, MD, FRCS.

“If you're going to be embarking upon triplet based therapy, as Arasens has now clearly demonstrated the potential advantage, having really healthy and productive and efficient conversations with your integrated cancer care team is paramount,” says Neal D. Shore, MD, FACS.

Investigators of a recent study presented at the 2022 ASCO Genitourinary Cancers Symposium reported favorable outcomes of pembrolizumab in patients with renal cell carcinoma at 30-month follow up.

In this interview, lead author Benjamin Lowentritt, MD, FACS, discusses why the findings of the study, "Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide," are so important in future counseling for mCSPC.

Long-term follow-up from the CheckMate 9ER trial continued to show that first-line treatment with nivolumab plus cabozantinib was associated with a health-related quality-of-life benefit over treatment with sunitinib in patients with advanced renal cell carcinoma .

Efficacy and safety data from the final analysis of the retrospective CaboCHECK trial support the use of cabozantinib in patients with advanced or metastatic renal cell carcinoma after progression on immunotherapy.

Despite missing the primary end point, avelumab did demonstrate notable clinical activity and a favorable safety profile in the phase 2 ARIES trial.

“I think the notable finding is the fact that the overall detection rate is very high, even at low PSA levels,” says David M. Schuster, MD, FACR.

“I do think that this helps inform how to choose an agent for this specific stage of the disease,” says Benjamin Lowentritt, MD, FACS.

“I think this data are very compelling,” says Neal D. Shore, MD, FACS.

Treatment with tivozanib was associated with a fivefold increased likelihood of experiencing long-term progression-free survival compared to treatment with sorafenib.

Immunotherapy with or without radiotherapy did not demonstrate significant efficacy in patients with advanced squamous cell carcinoma of the penis, according to findings from the phase 2 PERICLES trial.

“These are consistent results that continue to demonstrate a disease-free survival benefit of pembrolizumab adjuvant versus placebo,” says Toni K. Choueiri, MD.

The investigators concluded that time to event end points and response rates were similar regardless of which first-line immunotherapy was administered.

“I do think that this helps inform how to choose an agent for this specific stage of the disease,” says Benjamin Lowentritt, MD, FACS.

A recent study suggests that patients with adrenocortical carcinoma at low-intermediate risk of recurrence do not derive significant benefit from postoperative adjuvant mitotane treatment.

“I think that this updated analysis of KEYNOTE-564 further supports adjuvant pembrolizumab as a new standard of care for patients with RCC with high risk of recurrence,” said Toni K. Choueiri, MD.

The combination of the PD-L1 inhibitor avelumab and the tyrosine kinase inhibitor axitinib showed promise as a neoadjuvant therapy for patients with high-risk, non-metastatic clear-cell renal cell carcinoma, according to findings from the NeoAvAx trial.

First-line tivozanib in patients with metastatic renal cell carcinoma was reported to be safe, tolerable, and capable of producing similar clinical activity as other tyrosine kinase inhibitors used in this setting.

The final overall survival analysis from the phase 3 CheckMate 9ER trial continued to show a benefit with frontline nivolumab/cabozantinib versus sunitinib in patients with advanced renal cell carcinoma.

Lead study author Chung-Han Lee, MD, PhD, said that while the findings were “disappointing from a biomarker development standpoint,” the results confirm the effectiveness of the regimen across various lines of treatment.

An analysis of the phase 2 TITAN-RCC trial found multiple immune cell factors associated with high rates of response to nivolumab/ipilimumab in advanced renal cell carcinoma.

Neoadjuvant cabozantinib was safe and induced a reduction in tumor size in all patients with locally advanced nonmetastatic clear cell renal cell carcinoma enrolled in a phase 2 trial.

“I think, in general, patients with hereditary upper tract cancer may be under-recognized and under-referred for genetic evaluation,” says Hong Truong, MD.

The combo of the PARP inhibitor niraparib and the multikinase inhibitor cabozantinib showed positive early efficacy and safety signals in patients with metastatic urothelial carcinoma or renal cell carcinoma.

BAYOU trial results showed no significant PFS boost in all-comer population with addition of olaparib to frontline durvalumab in metastatic urothelial carcinoma, but potential benefit for combo was observed in HRR-mutation–positive subgroup.

“This first disclosure of data supports the ongoing phase 2 and 3 programs evaluating enfor-tumab vedotin alone or in combination with pembrolizumab in MIBC,” said Daniel P. Petrylak, MD.

“These data support further evaluation of antibody-drug conjugate/checkpoint inhibitor combination [therapy] in metastatic urothelial cancer in the platinum-refractory setting and probably in earlier lines of therapy in a different patient population,” says Petros Grivas, MD, PhD.